SCHEMBL4254863

SCHEMBL4254863

O=[N+]([O-])c1cccc(C=NNc2cc(N3CCOCC3)nc(N3CCOCC3)n2)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 9/20 0.75
▸ KDM4E B2RXH2 8/20 0.71
▸ MAPT P10636 8/20 0.71
▸ SENP6 Q9GZR1 6/20 0.71
▸ SENP7 Q9BQF6 5/20 0.71
▸ ALDH1A1 P00352 4/20 0.71
▸ HPGD P15428 1/20 0.71
▸ KMT2A Q03164 6/20 0.63
▸ MEN1 O00255 5/20 0.63
▸ POLB P06746 3/20 0.63
▸ MAPK1 P28482 2/20 0.63
▸ NSD2 O96028 2/20 0.63
▸ MPI P34949 1/20 0.63
▸ APAF1 O14727 4/20 0.60
▸ HTT P42858 3/20 0.60
▸ GAA P10253 3/20 0.60
▸ SENP8 Q96LD8 2/20 0.57
▸ PPP1CA P62136 1/20 0.57
▸ NPC1 O15118 1/20 0.56
▸ RAB9A P51151 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4254859 1.00 LMNA (0.75) LMNAKDM4EMAPTSENP6SENP7
SCHEMBL11900273 0.83 KDM4E (1.00) LMNAKDM4EMAPTSENP6SENP7
SCHEMBL1443164 0.83 KDM4E (1.00) LMNAKDM4EMAPTSENP6SENP7
SCHEMBL18330253 0.83 MAPT (1.00) LMNAKDM4EMAPTSENP6SENP7
SCHEMBL11900788 0.83 MAPT (1.00) LMNAKDM4EMAPTSENP6SENP7
SCHEMBL11981638 0.83 MAPT (1.00) LMNAKDM4EMAPTSENP6SENP7
SCHEMBL13576487 0.78 LMNA (0.81) LMNAMAPTALDH1A1KMT2AMEN1
Water SCHEMBL17200138 0.75 KDM4E (0.74) LMNAKDM4EMAPTSENP6SENP7
SCHEMBL1443113 0.74 MAPT (0.82) LMNAKDM4EMAPTSENP6SENP7
SCHEMBL11981855 0.74 MAPT (0.82) LMNAKDM4EMAPTSENP6SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215765-A1 Neuroprotective compounds for treating optic neuropathies THE JOHNS HOPKINS UNIVERSITY (US) 2009-08-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215765-A1 Neuroprotective compounds for treating optic neuropathies NLN, GAP43, AIFM1 LMNA 1628/4885KDM4E 4215/4885MAPT 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback